Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Dyadic International (NQ: DYAI ) 1.040 -0.060 (-5.45%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Dyadic International < Previous 1 2 3 4 5 6 Next > “Dyadic International Inc. (NASDAQ: DYAI): Zacks Small-Cap Research Indicates Valuation at $9.00 per Share” January 05, 2024 Via AB Newswire “Dyadic International (NASDAQ: DYAI) Revolutionizing Pharma with Innovative C1 Technology for Global Protein Development” January 02, 2024 Via AB Newswire Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference January 02, 2024 From Dyadic International, Inc. Via GlobeNewswire “2024 Market Outlook: SmallCap Radar Stocks Unveiled”: DYAI, SKYX, QUBT, KNW, VTAK December 28, 2023 Via AB Newswire Topics Intellectual Property Exposures Intellectual Property Recap: Dyadic International Q3 Earnings November 08, 2023 Via Benzinga “Dyadic International Inc. (NASDAQ: DYAI) Advances Biopharmaceutical Innovations and Vaccine Manufacturing Globally” December 21, 2023 Via AB Newswire Exposures COVID-19 CryptoNewsBreaks – Innovators and Ideas Showcased at 12th Annual Benchmark Discovery Conference December 19, 2023 Via Investor Brand Network InvestorNewsBreaks – Standouts from 12th Annual Benchmark Discovery Conference Featured in Nasdaq Article December 13, 2023 Via Investor Brand Network Dyadic Attends Investor Events in December November 30, 2023 From Dyadic International, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's After-Market Session November 29, 2023 Via Benzinga Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate November 29, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa November 20, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic to Present at Industry Events in November October 30, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023 October 25, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic Appoints Doug Pace to Its Executive Leadership Team October 09, 2023 From Dyadic International, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Friday's After-Market Session October 06, 2023 Via Benzinga 12 Health Care Stocks Moving In Thursday's Pre-Market Session October 05, 2023 Via Benzinga Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic October 05, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic to Present at Industry and Investor Events in October September 29, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells September 26, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus™ September 19, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic to Present at BioProcess International September 12, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin August 07, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023 July 26, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate July 24, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic Announced an MoU with Bangladesh’s State-Owned Pharmaceutical Company to Facilitate Biopharmaceutical Research and Biomanufacturing Capacity June 21, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic to Participate at Upcoming Events in June June 01, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic to Participate at Two Industry Events in May May 10, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic Announces Collaboration to Commercialize Animal-Free Alternative Proteins Using Dapibus™ May 08, 2023 From Dyadic International, Inc. Via GlobeNewswire Dyadic to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023 April 26, 2023 From Dyadic International, Inc. Via GlobeNewswire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.